JP2022547574A5 - - Google Patents

Info

Publication number
JP2022547574A5
JP2022547574A5 JP2022516046A JP2022516046A JP2022547574A5 JP 2022547574 A5 JP2022547574 A5 JP 2022547574A5 JP 2022516046 A JP2022516046 A JP 2022516046A JP 2022516046 A JP2022516046 A JP 2022516046A JP 2022547574 A5 JP2022547574 A5 JP 2022547574A5
Authority
JP
Japan
Prior art keywords
spik
sequence including
seq
amino acids
isolated antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022516046A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022547574A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/046782 external-priority patent/WO2021050217A1/en
Publication of JP2022547574A publication Critical patent/JP2022547574A/ja
Publication of JP2022547574A5 publication Critical patent/JP2022547574A5/ja
Priority to JP2025159797A priority Critical patent/JP2026012693A/ja
Pending legal-status Critical Current

Links

JP2022516046A 2019-09-11 2020-08-18 抗セリンプロテアーゼインヒビターｋａｚａｌ（ｓｐｉｋ）抗体のエピトープ Pending JP2022547574A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025159797A JP2026012693A (ja) 2019-09-11 2025-09-26 抗セリンプロテアーゼインヒビターｋａｚａｌ（ｓｐｉｋ）抗体のエピトープ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962899024P 2019-09-11 2019-09-11
US62/899,024 2019-09-11
PCT/US2020/046782 WO2021050217A1 (en) 2019-09-11 2020-08-18 Epitopes of anti-serine protease inhibitor kazal (spik) antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025159797A Division JP2026012693A (ja) 2019-09-11 2025-09-26 抗セリンプロテアーゼインヒビターｋａｚａｌ（ｓｐｉｋ）抗体のエピトープ

Publications (2)

Publication Number Publication Date
JP2022547574A JP2022547574A (ja) 2022-11-14
JP2022547574A5 true JP2022547574A5 (https=) 2023-09-04

Family

ID=72243286

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022516046A Pending JP2022547574A (ja) 2019-09-11 2020-08-18 抗セリンプロテアーゼインヒビターｋａｚａｌ（ｓｐｉｋ）抗体のエピトープ
JP2025159797A Pending JP2026012693A (ja) 2019-09-11 2025-09-26 抗セリンプロテアーゼインヒビターｋａｚａｌ（ｓｐｉｋ）抗体のエピトープ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025159797A Pending JP2026012693A (ja) 2019-09-11 2025-09-26 抗セリンプロテアーゼインヒビターｋａｚａｌ（ｓｐｉｋ）抗体のエピトープ

Country Status (7)

Country Link
US (1) US20240043512A1 (https=)
EP (1) EP4028132A1 (https=)
JP (2) JP2022547574A (https=)
KR (1) KR20220080098A (https=)
CN (1) CN114901699A (https=)
CA (1) CA3150538A1 (https=)
WO (1) WO2021050217A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12377162B2 (en) * 2019-07-08 2025-08-05 Imcare Biotech, Llc Anti-serine protease inhibitor kazal (SPIK) antibodies, immunoconjugates, and methods of use

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
EP0731106B1 (en) 1993-10-01 2004-11-17 Teikoku Hormone Mfg. Co., Ltd. Dolastatin derivatives
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6248564B1 (en) 1997-08-29 2001-06-19 Harvard University Mutant MHC class I molecules
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
CA2467242A1 (en) 2001-11-20 2003-05-30 Seattle Genetics, Inc. Treatment of immunological disorders using anti-cd30 antibodies
US20050180972A1 (en) 2002-07-31 2005-08-18 Wahl Alan F. Anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
EP2478912B1 (en) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
CA2703140A1 (en) * 2007-10-25 2009-04-30 Viventia Biotech Inc. Antibodies against a cancer-associated epitope of variant hnrnpg and uses thereof
RU2583270C2 (ru) 2009-04-01 2016-05-10 Дженентек, Инк. АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
WO2012078752A2 (en) * 2010-12-09 2012-06-14 Philadelphia Health & Education Corporation D/B/A Serine protease inhibitor kazal antibodies
CA2898472C (en) * 2013-02-15 2023-03-07 Immunomedics, Inc. Chimeric and humanized anti-histone antibodies
WO2015164757A1 (en) * 2014-04-25 2015-10-29 Oregon Health & Science University Methods of viral neutralizing antibody epitope mapping
BR112018070097A2 (pt) * 2016-03-29 2019-02-12 Obi Pharma, Inc. anticorpo, hibridoma, composição farmacêutica, método para tratar câncer em um indivíduo, método para inibir a proliferação de células cancerígenas, método para diagnosticar o câncer em um indivíduo, método para tratar um paciente humano, método para fazer imagens de um indivíduo, conjugado de fármaco-anticorpo (adc), método para tratar câncer, anticorpo biespecífico e método para preparar uma população de anticorpos homogêneos
US12180301B2 (en) 2018-03-06 2024-12-31 Imcare Biotech, Llc Serine protease inhibitor kazal (SPIK) compositions and methods
CN109678950B (zh) * 2019-01-08 2022-05-10 灏灵赛奥（天津）生物科技有限公司 spink1抗原、能够特异性结合spink1的抗体及其功能片段及其应用和产品
US12377162B2 (en) * 2019-07-08 2025-08-05 Imcare Biotech, Llc Anti-serine protease inhibitor kazal (SPIK) antibodies, immunoconjugates, and methods of use

Similar Documents

Publication Publication Date Title
RU2504551C2 (ru) Белки, связывающие антиген фактор роста, подобный гепаринсвязывающему эпидермальному фактору роста
CN102421795B (zh) 针对肌钙蛋白i的抗体及其使用方法
US10197573B2 (en) HCV core lipid binding domain monoclonal antibodies
JP2007527406A5 (https=)
FI3718564T3 (fi) Uusia anti-IL 13 -vasta-aineita ja niiden käyttöjä
JP2020516603A5 (https=)
JP2009517057A5 (https=)
JP2005528914A5 (https=)
RU2007118670A (ru) Ангиопоэтин-2-специфические связывающие агенты
JP2025111457A5 (https=)
EP3983806A1 (en) Multiplex competition assay for profiling binding epitopes of affinity agents for clinical diagnostics use
JP2023518225A5 (https=)
JP2020189843A5 (https=)
JP2021515597A5 (https=)
JP2022540079A5 (https=)
CN114650866B (zh) 新的用于诊断的分子
JP2022547574A5 (https=)
CN114578066B (zh) 检测β-淀粉样蛋白的产品和方法
JP5821198B2 (ja) 抗ｉｌ２８ｂ抗体及びこれを用いたｉｌ２８ｂの測定方法
KR102078879B1 (ko) 돼지파보바이러스에 특이적인 단일클론항체 및 이의 용도
WO2024093042A1 (zh) 一种抗bsa的兔单克隆抗体及其应用
WO2022238481A1 (en) Antibodies
KR20230124280A (ko) 메르스 코로나 바이러스의 뉴클레오캡시드 단백질에 특이적인 진단용 항체 및 이의 용도
CN115210256A (zh) 用于前列腺癌诊断的新方法和化合物
JP2023156197A5 (https=)